BIDMC Study in NEJM Reports Progress in Preventing Bleeding in Atrial Fibrillation Patients Undergoing Stenting
Beth Israel Lahey HealthA new study led by clinician-researchers at Beth Israel Deaconess Medical Center (BIDMC) testing the safety and effectiveness of anticoagulant strategies for patients with atrial fibrillation who undergo stenting procedures has shown that therapies combining the anticoagulant drug rivaroxaban with either single or dual anti-platelet therapy (DAPT) were more effective in preventing bleeding complications than the current standard of care.